Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2023 09:15 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

Rapid and sustained efficacy demonstrated in GPP patients after only a single dose, achieving primary endpoint at Week 4Flare control sustained on monthly subcutaneous doses through Week 16Imsidolimab...
April 06, 2023 16:15 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors

SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the...
March 27, 2023 18:50 ET | Source: AnaptysBio, Inc.

AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial

Results published in The New England Journal of Medicine and presented simultaneously at ESMO Virtual Plenary and SGO Annual Meeting72% and 36% reduction in the risk of disease progression or death...
March 01, 2023 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Initiating a global Phase 2b trial for rosnilimab (PD-1 agonist) to treat rheumatoid arthritis anticipated Q3 2023Initiating a global Phase 2b trial for ANB032 (BTLA agonist) to treat atopic...
February 27, 2023 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics today announced that Dan...
January 13, 2023 09:00 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Stock Repurchase Plan

SAN DIEGO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
January 05, 2023 16:05 ET | Source: AnaptysBio, Inc.

AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies

Advancing rosnilimab, its PD-1 agonist, into a global Phase 2b trial to treat rheumatoid arthritis with study initiation in Q3 2023Advancing ANB032, its BTLA agonist, into a global Phase 2b trial to...
December 02, 2022 09:00 ET | Source: AnaptysBio, Inc.

AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer...
November 21, 2022 13:56 ET | Source: AnaptysBio, Inc.

AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference

SAN DIEGO, Nov. 21, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
November 09, 2022 14:10 ET | Source: AnaptysBio, Inc.

AnaptysBio to Participate in Upcoming November Investor Conferences

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...